Скачать с ютуб Collaboration with the Vall d’Hebron Institute of Oncology (VHIO) в хорошем качестве

Collaboration with the Vall d’Hebron Institute of Oncology (VHIO)

Based on 2019 data, ~44% of US patients with cancer were eligible for immunotherapy treatment, but only less than 13% of patients responded to it. Ultra-sensitive MRD testing technology like NeXT Personal® can help clinicians track patient response to immunotherapy, and help inform whether the therapy is working. Here we highlight our collaboration with Dr Rodrigo Toledo from the Vall d’Hebron Institute of Oncology (VHIO) in which researchers used NeXT Personal to monitor patient response to immunotherapy.